| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Adrianne F Pike, Ildikò Szabò, Robert Veerhuis, Luigi Bubacc. The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson's disease. NPJ Parkinson's disease. vol 8. issue 1. 2022-03-25. PMID:35332154. |
if this is the case, a sufficient dopamine supply would ensure that microglia remain under control, but as dopamine is gradually siphoned from the neurons by microglial demand, nlrp3 inflammasome activation and kv1.3 activity would progressively intensify to promote each of the three major facets of pd pathology: α-synuclein aggregation, microglia-mediated neuroinflammation, and dopaminergic neurodegeneration. |
2022-03-25 |
2023-08-13 |
Not clear |
| Adrianne F Pike, Ildikò Szabò, Robert Veerhuis, Luigi Bubacc. The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson's disease. NPJ Parkinson's disease. vol 8. issue 1. 2022-03-25. PMID:35332154. |
risk factors overlapping to varying degrees to render brain regions susceptible to such a mechanism would include a high density of microglia, an initially sufficient supply of dopamine, and poor insulation of the dopaminergic neurons by myelin. |
2022-03-25 |
2023-08-13 |
Not clear |
| Akhil A Vinithakumari, Piyush Padhi, Belen Hernandez, Susanne Je-Han Lin, Aaron Dunkerson-Kurzhumov, Lucas Showman, Matthew Breitzman, Caroline Stokes, Yousuf Sulaiman, Chandra Tangudu, Deepa A Kuttappan, Muhammed S Muyyarikkandy, Auriel A Willette, Gregory J Phillips, Vellareddy Anantharam, Ann Perera, Brett A Sponseller, Anumantha Kanthasamy, Shankumar Mooyott. Clostridioides difficile Infection Dysregulates Brain Dopamine Metabolism. Microbiology spectrum. 2022-03-24. PMID:35323033. |
the manuscript reports that c. difficile infection (cdi), predisposed by antibiotic-induced gut dysbiosis, causes significant alterations in dopamine metabolism in major dopaminergic brain regions in mice ( |
2022-03-24 |
2023-08-13 |
mouse |
| M Angela Cenci, Katrine Skovgård, Per Odi. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology. 2022-03-16. PMID:35292330. |
these complications are attributed to the combined effects of dopaminergic degeneration and non-physiological reinstatement of dopamine transmission by the standard oral medications. |
2022-03-16 |
2023-08-13 |
Not clear |
| Richard M Kostrzew. Neonatal 6-hydroxydopamine lesioning of rats and dopaminergic neurotoxicity: proposed animal model of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). 2022-03-13. PMID:35279767. |
the n6-ohda-lesioned rat is posed as a reasonable animal model for pd: (a) the magnitude of dopaminergic neuronal destruction is expansive, (b) mapping of dopaminergic denervation has been defined, (c) effects on dopamine (da) receptor alterations have been elucidated (d) as well as changes in receptor sensitivity status, (e) reactive sprouting of serotoninergic innervation (i.e. |
2022-03-13 |
2023-08-13 |
human |
| Savannah M Rocha, Collin M Bantle, Tawfik Aboellail, Debotri Chatterjee, Richard J Smeyne, Ronald B Tjalken. Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice. Neurobiology of disease. 2022-03-08. PMID:35257879. |
deficits include loss of dopaminergic neurons (dan) in the substantia nigra pars compacta (snpc), decreased dopamine levels and aggregation of misfolded alpha-synuclein (p129). |
2022-03-08 |
2023-08-13 |
mouse |
| Roshan Cools, Jorryt G Tichelaar, Rick C G Helmich, Bastiaan R Bloem, Rianne A J Esselink, Katrijn Smulders, Monique H M Timme. Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease. Progress in brain research. vol 269. issue 1. 2022-03-06. PMID:35248200. |
we describe the history of research supporting the dopamine overdose hypothesis, which accounts for the large within-patient variability in dopaminergic medication effects across different tasks by referring to the spatially non-uniform pattern of dopamine depletion in dorsal versus ventral striatum. |
2022-03-06 |
2023-08-13 |
Not clear |
| Roshan Cools, Jorryt G Tichelaar, Rick C G Helmich, Bastiaan R Bloem, Rianne A J Esselink, Katrijn Smulders, Monique H M Timme. Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease. Progress in brain research. vol 269. issue 1. 2022-03-06. PMID:35248200. |
in the second part of this chapter we review recent studies addressing the large individual variability in the negative side effects of dopaminergic medication on functions that implicate dopamine, such as value-based learning and choice. |
2022-03-06 |
2023-08-13 |
Not clear |
| Jonathan R Reinwald, Natalia Gass, Anne S Mallien, Alexander Sartorius, Robert Becker, Markus Sack, Claudia Falfan-Melgoza, Christian Clemm von Hohenberg, Damiana Leo, Natascha Pfeiffer, Anthonieke Middelman, Andreas Meyer-Lindenberg, Judith R Homberg, Wolfgang Weber-Fahr, Peter Gas. Dopamine transporter silencing in the rat: systems-level alterations in striato-cerebellar and prefrontal-midbrain circuits. Molecular psychiatry. 2022-03-05. PMID:35246636. |
silencing of dopamine transporter (dat), a main controlling factor of dopaminergic signaling, results in biochemical and behavioral features characteristic for neuropsychiatric diseases with presumed hyperdopaminergia including schizophrenia, attention deficit hyperactivity disorder (adhd), bipolar disorder, and obsessive-compulsive disorder (ocd). |
2022-03-05 |
2023-08-13 |
rat |
| Amgad Droby, Moran Artzi, Hedva Lerman, R Matthew Hutchison, Dafna Ben Bashat, Nurit Omer, Tanya Gurevich, Avi Orr-Urtreger, Batsheva Cohen, Jesse M Cedarbaum, Einat Even Sapir, Nir Giladi, Anat Mirelman, Avner Thale. Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers. NPJ Parkinson's disease. vol 8. issue 1. 2022-03-04. PMID:35241697. |
dopamine transporter (dat)-spectral positron emission computed tomography is widely used for capturing functional nigrostriatal dopaminergic activity. |
2022-03-04 |
2023-08-13 |
human |
| Cecilia Boccalini, Giulia Carli, Andrea Pilotto, Alessandro Padovani, Daniela Peran. Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes. Neurobiology of disease. 2022-02-27. PMID:35219854. |
the male vulnerability emerged also in the motor system in the same subtypes with motor impairment associated with a lower dopamine binding in the putamen and more severe widespread connectivity alterations in the nigrostriatal dopaminergic pathway in males than in females. |
2022-02-27 |
2023-08-13 |
Not clear |
| Ning Wang, Rui Li, Bainian Feng, Yuliang Cheng, Yahui Guo, He Qia. Chicoric Acid Prevents Neuroinflammation and Neurodegeneration in a Mouse Parkinson's Disease Model: Immune Response and Transcriptome Profile of the Spleen and Colon. International journal of molecular sciences. vol 23. issue 4. 2022-02-26. PMID:35216146. |
in this study, we observe that ca prevented dopaminergic neuronal lesions, motor deficits and glial activation in pd mice, along with the increment in striatal brain-derived neurotrophic factor (bdnf), dopamine (da) and 5-hydroxyindoleacetic acid (5-ht). |
2022-02-26 |
2023-08-13 |
mouse |
| Paolo Solla, Tommaso Ercoli, Carla Masala, Gianni Orofino, Laura Fadda, Davide Giacomo Corda, Ignazio Roberto Zarbo, Mario Meloni, Elia Sechi, Caterina Francesca Bagella, Giovanni Defazi. Rasagiline Withdrawal Syndrome in Parkinson's Disease. Brain sciences. vol 12. issue 2. 2022-02-25. PMID:35203982. |
however, symptoms of withdrawal of dopamine replacement therapies (drt) are not simply limited to dopamine agonists tapering, as observed in pd patients on deep brain stimulation after dopaminergic drugs withdrawal related to surgery. |
2022-02-25 |
2023-08-13 |
Not clear |
| Sara Redenšek, Tanja Blagus, Maja Trošt, Vita Dolža. Serotonin-Related Functional Genetic Variants Affect the Occurrence of Psychiatric and Motor Adverse Events of Dopaminergic Treatment in Parkinson's Disease: A Retrospective Cohort Study. Journal of personalized medicine. vol 12. issue 2. 2022-02-25. PMID:35207756. |
the serotonergic system is important in parkinson's disease (pd) pathogenesis as it can take over dopamine production after a large portion of dopaminergic neurons is lost through neurodegeneration. |
2022-02-25 |
2023-08-13 |
Not clear |
| Teresa Alberts, Veronica Antipova, Carsten Holzmann, Alexander Hawlitschka, Oliver Schmitt, Jens Kurth, Jan Stenzel, Tobias Lindner, Bernd J Krause, Andreas Wree, Martin Wit. Olfactory Bulb D Toxins. vol 14. issue 2. 2022-02-24. PMID:35202123. |
the first central relay of the olfactory pathway, the olfactory bulb (ob), depends, among other things, on an intact, functional crosstalk between dopaminergic interneurons and dopamine receptors (d |
2022-02-24 |
2023-08-13 |
Not clear |
| Tao He, Chaojun Han, Chun Liu, Jiaojiao Chen, Huicui Yang, Longtai Zheng, John L Waddington, Xuechu Zhe. Dopamine D1 receptors mediate methamphetamine-induced dopaminergic damage: involvement of autophagy regulation via the AMPK/FOXO3A pathway. Psychopharmacology. 2022-02-22. PMID:35190859. |
dopamine d1 receptors mediate methamphetamine-induced dopaminergic damage: involvement of autophagy regulation via the ampk/foxo3a pathway. |
2022-02-22 |
2023-08-13 |
Not clear |
| Adrianne F Pike, Francesca Longhena, Gaia Faustini, Jean-Marc van Eik, Iris Gombert, Maaike A C Herrebout, Mona M H E Fayed, Michele Sandre, Tatiana Varanita, Charlotte E Teunissen, Jeroen J M Hoozemans, Arianna Bellucci, Robert Veerhuis, Luigi Bubacc. Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. Journal of neuroinflammation. vol 19. issue 1. 2022-02-17. PMID:35172843. |
parkinson's disease (pd) is characterized by the loss of nigral dopaminergic neurons leading to impaired striatal dopamine signaling, α-synuclein- (α-syn-) rich inclusions, and neuroinflammation. |
2022-02-17 |
2023-08-13 |
mouse |
| Michele Salemi, Giuseppe Lanza, Maria Paola Mogavero, Filomena I I Cosentino, Eugenia Borgione, Roberta Iorio, Giovanna Maria Ventola, Giovanna Marchese, Maria Grazia Salluzzo, Maria Ravo, Raffaele Ferr. A Transcriptome Analysis of mRNAs and Long Non-Coding RNAs in Patients with Parkinson's Disease. International journal of molecular sciences. vol 23. issue 3. 2022-02-15. PMID:35163455. |
clinical symptoms include the progressive loss of dopaminergic neurons in the substantia nigra of the midbrain, which leads to striatal dopamine deficiency and, subsequently, causes motor dysfunction. |
2022-02-15 |
2023-08-13 |
human |
| Elham Ghanavati, Mohammad Ali Salehinejad, Lorena De Melo, Michael A Nitsche, Min-Fang Ku. NMDA receptor-related mechanisms of dopaminergic modulation of tDCS-induced neuroplasticity. Cerebral cortex (New York, N.Y. : 1991). 2022-02-15. PMID:35165699. |
eleven healthy, right-handed volunteers received anodal tdcs (1 ma, 13 min) over the left motor cortex combined with dopaminergic agents (the d2 receptor agonist bromocriptine, levodopa for general dopamine enhancement, or placebo) and the partial nmda receptor agonist d-cycloserine (dosages of 50, 100, and 200 mg, or placebo). |
2022-02-15 |
2023-08-13 |
human |
| Li Zhou, Qian Xie, Quanyun Zhang, Mengxi Hu, Tengfei Ma, Hong Xi. Dexmedetomidine attenuates motor deficits via restoring the function of neurons in the nigrostriatal circuit in Parkinson's disease model mice. European journal of pharmacology. 2022-02-12. PMID:35150656. |
the dex acted on the neurons in the nigrostriatal circuits, including activation of dopaminergic neurons and the reduction of the excitabilities of striatal neurons via dopamine d2 receptors. |
2022-02-12 |
2023-08-13 |
mouse |